Autonomix Medical Inc Financials
This page shows Autonomix Medical Inc (AMIX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
AMIX is operating as a cash-funded development company, with equity capital carrying research and overhead instead of customer cash.
From FY2024 to FY2025, net loss narrowed from-$15.4M to-$11.4M . But operating cash burn worsened from-$6.6M to-$8.3M , so accounting improvement and cash consumption moved in opposite directions; that usually means the operating platform itself did not get meaningfully cheaper.
The balance sheet is equity-funded: FY2025 cash of
Spending reflects a broader development buildout, with R&D at
Financial Health Signals
Based on FY2026 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Autonomix Medical Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Autonomix Medical Inc carries a low D/E ratio of 0.29, meaning only $0.29 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 96/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 4.45, Autonomix Medical Inc holds $4.45 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 88/100.
Autonomix Medical Inc generates a -283.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -140.9% the prior year.
Autonomix Medical Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Autonomix Medical Inc generates $0.73 in operating cash flow (-$12.3M OCF vs -$16.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Autonomix Medical Inc generated $0 in revenue in fiscal year 2026.
Autonomix Medical Inc's EBITDA was -$17.0M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 49.3% from the prior year.
Autonomix Medical Inc reported -$16.7M in net income in fiscal year 2026. This represents a decrease of 46.5% from the prior year.
Cash & Balance Sheet
Autonomix Medical Inc generated -$12.3M in free cash flow in fiscal year 2026, representing cash available after capex. This represents a decrease of 48.6% from the prior year.
Autonomix Medical Inc held $7.0M in cash against $0 in long-term debt as of fiscal year 2026.
Autonomix Medical Inc had 11M shares outstanding in fiscal year 2026. This represents an increase of 356.9% from the prior year.
Margins & Returns
Autonomix Medical Inc's ROE was -283.6% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is down 142.7 percentage points from the prior year.
Capital Allocation
Autonomix Medical Inc invested $7.1M in research and development in fiscal year 2026. This represents an increase of 51.2% from the prior year.
Autonomix Medical Inc invested $10K in capex in fiscal year 2026, funding long-term assets and infrastructure. This represents a decrease of 28.6% from the prior year.
AMIX Income Statement
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $0 | $0 | $0 | N/A | $0 | $0 | $0 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $1.7M-27.2% | $2.4M+48.6% | $1.6M | N/A | $1.0M-11.1% | $1.2M+23.1% | $954K |
| SG&A Expenses | N/A | $1.6M-68.7% | $5.2M+182.7% | $1.8M | N/A | $1.7M+2.5% | $1.7M-7.6% | $1.8M |
| Operating Income | N/A | -$3.3M+55.6% | -$7.5M-120.2% | -$3.4M | N/A | -$2.7M+3.1% | -$2.8M-3.0% | -$2.8M |
| Interest Expense | N/A | $0 | $0 | $0 | N/A | $100K0.0% | $100K+143.9% | $41K |
| Income Tax | N/A | $0 | $0 | $0 | N/A | $0 | $0 | $0 |
| Net Income | N/A | -$3.3M+56.2% | -$7.5M-123.3% | -$3.3M+70.8% | -$11.4M-320.7% | -$2.7M+3.4% | -$2.8M-4.0% | -$2.7M |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
AMIX Balance Sheet
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.6M-25.6% | $10.2M+28.7% | $7.9M-11.8% | $9.0M-8.3% | $9.8M-18.0% | $12.0M+122.5% | $5.4M-24.3% | $7.1M |
| Current Assets | $7.6M-25.6% | $10.2M+29.1% | $7.9M-12.1% | $9.0M-6.6% | $9.6M-19.5% | $11.9M+122.9% | $5.4M-24.3% | $7.1M |
| Cash & Equivalents | $7.0M-29.5% | $9.9M+32.9% | $7.5M-12.9% | $8.6M-6.0% | $9.1M-22.7% | $11.8M+129.4% | $5.2M-23.6% | $6.8M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $1.7M+3.3% | $1.6M+11.0% | $1.5M-24.3% | $2.0M+15.1% | $1.7M-24.0% | $2.2M-4.2% | $2.3M+29.7% | $1.8M |
| Current Liabilities | $1.7M+3.3% | $1.6M+11.0% | $1.5M-24.3% | $2.0M+15.1% | $1.7M-24.0% | $2.2M+78.6% | $1.3M+64.7% | $763K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $5.9M-31.1% | $8.6M+32.8% | $6.4M-8.3% | $7.0M-13.2% | $8.1M-16.6% | $9.7M+220.6% | $3.0M-42.7% | $5.3M |
| Retained Earnings | -$67.1M-4.1% | -$64.4M-5.3% | -$61.2M-13.9% | -$53.7M-6.6% | -$50.4M-6.8% | -$47.2M-6.1% | -$44.5M-6.7% | -$41.7M |
AMIX Cash Flow Statement
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.9M+2.6% | -$3.0M+22.2% | -$3.8M-46.6% | -$2.6M+68.5% | -$8.3M-258.9% | -$2.3M-44.2% | -$1.6M+13.8% | -$1.9M |
| Capital Expenditures | $3K-57.1% | $7K | $0 | $0-100.0% | $14K+180.0% | $5K | $0-100.0% | $5K |
| Free Cash Flow | -$2.9M+2.7% | -$3.0M+22.0% | -$3.8M-46.6% | -$2.6M+68.5% | -$8.3M-258.7% | -$2.3M-44.5% | -$1.6M+14.1% | -$1.9M |
| Investing Cash Flow | -$3K+57.1% | -$7K | $0 | $0+100.0% | -$14K-180.0% | -$5K | $0+100.0% | -$5K |
| Financing Cash Flow | -$35K-100.6% | $5.4M+100.9% | $2.7M+31.5% | $2.1M-76.6% | $8.8M-1.9% | $9.0M | $0 | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
AMIX Financial Ratios
| Metric | Q4'26 | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | -38.1%+77.5pp | -115.6%-68.1pp | -47.4%+93.4pp | -140.9%-112.9pp | -27.9%+64.8pp | -92.7%-41.7pp | -51.0% |
| Return on Assets | N/A | -31.9%+62.0pp | -93.9%-56.8pp | -37.1%+79.3pp | -116.4%-93.7pp | -22.7%+29.6pp | -52.3%-14.2pp | -38.0% |
| Current Ratio | 4.45-1.7 | 6.18+0.9 | 5.31+0.7 | 4.57-1.1 | 5.63+0.3 | 5.31+1.1 | 4.26-5.0 | 9.27 |
| Debt-to-Equity | 0.29+0.1 | 0.19-0.0 | 0.23-0.0 | 0.28+0.1 | 0.21-0.0 | 0.23-0.5 | 0.77+0.4 | 0.34 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Autonomix Medical Inc's annual revenue?
Autonomix Medical Inc (AMIX) reported $0 in total revenue for fiscal year 2026. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Autonomix Medical Inc profitable?
No, Autonomix Medical Inc (AMIX) reported a net income of -$16.7M in fiscal year 2026.
What is Autonomix Medical Inc's EBITDA?
Autonomix Medical Inc (AMIX) had EBITDA of -$17.0M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
What is Autonomix Medical Inc's return on equity (ROE)?
Autonomix Medical Inc (AMIX) has a return on equity of -283.6% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Autonomix Medical Inc's free cash flow?
Autonomix Medical Inc (AMIX) generated -$12.3M in free cash flow during fiscal year 2026. This represents a -48.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Autonomix Medical Inc's operating cash flow?
Autonomix Medical Inc (AMIX) generated -$12.3M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.
What are Autonomix Medical Inc's total assets?
Autonomix Medical Inc (AMIX) had $7.6M in total assets as of fiscal year 2026, including both current and long-term assets.
What are Autonomix Medical Inc's capital expenditures?
Autonomix Medical Inc (AMIX) invested $10K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
How much does Autonomix Medical Inc spend on research and development?
Autonomix Medical Inc (AMIX) invested $7.1M in research and development during fiscal year 2026.
What is Autonomix Medical Inc's current ratio?
Autonomix Medical Inc (AMIX) had a current ratio of 4.45 as of fiscal year 2026, which is generally considered healthy.
What is Autonomix Medical Inc's debt-to-equity ratio?
Autonomix Medical Inc (AMIX) had a debt-to-equity ratio of 0.29 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Autonomix Medical Inc's return on assets (ROA)?
Autonomix Medical Inc (AMIX) had a return on assets of -219.9% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is Autonomix Medical Inc's cash runway?
Based on fiscal year 2026 data, Autonomix Medical Inc (AMIX) had $7.0M in cash against an annual operating cash burn of $12.3M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Autonomix Medical Inc's Piotroski F-Score?
Autonomix Medical Inc (AMIX) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Autonomix Medical Inc's earnings high quality?
Autonomix Medical Inc (AMIX) has an earnings quality ratio of 0.73x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Autonomix Medical Inc?
Autonomix Medical Inc (AMIX) scores 31 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.